Genocea rises on Phase II HSV data

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $0.94 to $11.59 on Tuesday after it said all six dosing combinations that included lead candidate GEN-003 met the primary endpoint in a Phase II dose optimization trial to treat herpes simplex virus type 2 (HSV-2) infection.

Patients in the highest dose group -- 60 ug per protein / 75 ug of adjuvant -- performed best among the groups on the primary endpoint, demonstrating a 55% reduction from baseline in viral shedding rate (p<0.0001). ...